Back to top

cancer: Archive

Ekta Bagri

PFE vs BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Pfizer and Bristol Myers are racing to strengthen oncology portfolios through deals, new drugs and pipelines ??? investors are weighing which stock stands out.

BMYPositive Net Change PFENegative Net Change

Sundeep Ganoria

ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?

IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.

RHHBYNegative Net Change BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change

Bryan Hayes

Bull of the Day: Cardinal Health (CAH)

This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.

CAHPositive Net Change

Bryan Hayes

Bull of the Day: Cardinal Health (CAH)

This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.

CAHPositive Net Change

Urmimala Biswas

Silver Economy Boom: Investing in Healthcare's Aging Tailwinds

An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.

ABTNegative Net Change BSXNegative Net Change AMGNNegative Net Change MDTNegative Net Change RMDNegative Net Change ABBVPositive Net Change

Ekta Bagri

Will BMY's Oncology Collaborations Drive Its Next Growth Phase?

BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.

BMYPositive Net Change PFENegative Net Change MRKPositive Net Change BNTXNegative Net Change

Kinjel Shah

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

JNJPositive Net Change PFENegative Net Change MRKPositive Net Change LLYNegative Net Change ABBVPositive Net Change FHTXNegative Net Change IBRXNegative Net Change

Kinjel Shah

3 Cancer-Focused Stocks Showing Strong Pipeline Progress

Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

PFENegative Net Change MRKPositive Net Change LLYNegative Net Change ABBVPositive Net Change FATENegative Net Change VSTMNegative Net Change RLAYPositive Net Change

Ekta Bagri

MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?

Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.

BMYPositive Net Change MRKPositive Net Change